Involvement of Th17 and Th1 effector responses in patients with Hepatitis B.
BACKGROUND
Local production of cytokines within the liver may play a pivotal role in the regulation of pathophysiological processes during inflammation. CD4+ T cells are regarded as the most prolific cytokine producers. The purpose of this study was to quantify intrahepatic expression of Th1, Th2, Th17, and Treg-associated cytokines or transcription factors in patients with acute hepatitis B or chronic hepatitis B (CHB) and to analyze their relative roles in the promotion and regulation of hepatitis B virus (HBV)-associated liver diseases.


METHODS
Distribution and expression of IL-17, IFN-gamma, IL-4, Foxp3, and other cytokines in liver tissues were detected by immunohistochemistry and real-time quantitative PCR. Patients with hepatitis B were compared with patients with chronic hepatitis C, primary biliary cirrhosis, alcoholic liver cirrhosis, and healthy controls.


RESULTS
The frequencies of intrahepatic IL-17 and IFN-gamma-producing cells in patients with HBV-associated liver dysfunction were much higher than that of IL-4 and Foxp3-positive cells. The level of the IL-17/IFN-gamma-positive cell ratio of patients with Child-Pugh class C (1.57+/-0.09) was much higher than that of patients with Child-Pugh class B (1.00+/-.02) or A (0.93+/-0.05). There are more IL-17-producing cells than IFN-gamma-producing cells accumulating in the liver with severe hepatocellular damage. Liver IL-17-producing cell infiltration was positively associated with the grade of liver inflammation in CHB and positively correlated to intrahepatic IL-8 expression (r=0.801, p<0.01) or neutrophil infiltration (r=0.917, p<0.01).


CONCLUSIONS
These results suggest that the balance of effector CD4+ Th responses (Th17 and Th1 responses) and regulatory response is an important element of immune regulation. Inappropriate, excessive, and non-specific Th17 and Th1 effector responses may be involved in the pathogenesis of HBV-associated liver inflammation and hepatocellular damage. Th17 response, especially, may exacerbate the inflammatory processes leading to liver failure. IL-17-mediating liver neutrophil recruitment via induction of IL-8 may be one potential mechanism of liver injury in patients with hepatitis B. An improved understanding of the factors that influence the differentiation and function of these cell types in vivo will be of great importance to the future development of immune therapies in HBV-associated liver disease.
Ye
Yufu
Y
Key Laboratory of Combined Multi-organ Transplantation, Ministry of Public Health, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, People's Republic of China.
Xie
Xiaojun
X
Yu
Jiwei
J
Zhou
Lin
L
Xie
Haiyang
H
Jiang
Guoping
G
Yu
Xiaobo
X
Zhang
Wenjin
W
Wu
Jian
J
Zheng
Shusen
S
D000328:Adult; D000368:Aged; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D016022:Case-Control Studies; D016207:Cytokines / Q000096:biosynthesis; D005260:Female; D006509:Hepatitis B / Q000150:complications / Q000276:immunology*; D006801:Humans; D020381:Interleukin-17 / Q000276:immunology*; D008099:Liver / Q000276:immunology / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology*; D050378:T-Lymphocytes, Regulatory / Q000276:immunology; D018417:Th1 Cells / Q000276:immunology*; D014157:Transcription Factors / Q000096:biosynthesis
D016207:Cytokines; D020381:Interleukin-17; D014157:Transcription Factors
Nat Immunol. 2005 Nov;6(11):1133-41
16200068
J Immunol. 1999 Feb 15;162(4):2347-52
9973514
Hepatology. 1997 Apr;25(4):1022-7
9096614
J Hepatol. 2009 May;50(5):980-9
19329213
Liver Int. 2006 Oct;26(8):912-9
16953830
Nat Med. 2007 Feb;13(2):139-45
17290272
J Autoimmun. 2009 Feb;32(1):43-51
19101114
Annu Rev Immunol. 2009;27:485-517
19132915
Immunol Rev. 2008 Jun;223:87-113
18613831
Hepatology. 2009 May;49(5 Suppl):S45-55
19399792
Hepatology. 2010 Jan;51(1):81-91
19842207
Nat Immunol. 2005 Nov;6(11):1123-32
16200070
Nature. 2006 May 11;441(7090):235-8
16648838
Cancer Res. 2009 Mar 1;69(5):2010-7
19244111
J Clin Invest. 1997 Jun 15;99(12):3025-33
9185527
Gastroenterology. 1999 Sep;117(3):645-52
10464141
J Hepatol. 2007 Oct;47(4):598-607
17692984
Int Rev Immunol. 1998;16(5-6):541-51
9646176
Ann Surg Oncol. 2008 Dec;15(12):3494-502
18830757
Annu Rev Immunol. 1995;13:29-60
7612225
Int Arch Allergy Immunol. 2001 Nov;126(3):179-84
11752873
J Virol. 2005 Aug;79(15):9369-80
16014900
Annu Rev Immunol. 1995;13:251-76
7612223
Clin Microbiol Infect. 2005 Jan;11(1):52-6
15649304
Hepatology. 2009 May;49(5 Suppl):S13-21
19399811
J Immunol. 1999 Jun 1;162(11):6503-9
10352265
Annu Rev Immunol. 2009;27:147-63
19302037
Hepatology. 2009 Feb;49(2):646-57
19177575
Hepatol Res. 2007 Apr;37(4):248-54
17397512
Hepatology. 1995 Jul;22(1):61-8
7601434
J Med Virol. 2003 Nov;71(3):376-84
12966542
Clin Liver Dis. 2007 Nov;11(4):727-59, vii-viii
17981227
Antivir Ther. 1998;3(Suppl 3):13-24
10726052
Nat Rev Immunol. 2005 Mar;5(3):215-29
15738952